Dr Reddy's Secures CDSCO Nod, Becomes First to Launch Elobixibat in India

Dr Reddy's is the first leading pharmaceutical company to obtain approval from the Central Drugs Standard Control Organisation (CDSCO) to introduce Elobixibat in India. Elobixibat works by preventing bile acids from being reabsorbed in the ileum, which results in higher levels of bile acids in the colon. This leads to a boost in bowel movements by enhancing colonic motility and fluid secretion, regardless of how quickly food moves through the digestive system.

Dr Reddy's Laboratories announced the introduction of a groundbreaking medication for treating chronic constipation. The drug firm based in Hyderabad said in a statement that the company will launch the drug in India with the brand name BixiBat.

"The launch of this first-in-class drug is the latest in our continued efforts to bring novel molecules to patients in India," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said.

He mentioned that the clinical trials for BixiBat have shown much improved and hopeful results, making it a revolutionary medication for treating chronic constipation and improving the current treatment standards in India.

Dr. Reddy's Laboratories, headquartered in Hyderabad, is a multinational pharmaceutical firm from India. Kallam Anji Reddy, who had prior experience at Indian Drugs and Pharmaceuticals Limited, established the company. Dr. Reddy produces and sells a diverse array of medications in both India and abroad.